temple longevity acquisition
Temple Acquires Longevous Is Longevity Science Bleeding Pharma Budgets
Temple’s $1.5 billion acquisition of Longevous signals a decisive bet that genetic longevity interventions will soon drive mainstream drug development, potentially reshaping pharma budgets. 35% faster trial recruitment and a unified patient registry are already cutting timelines, while early IND data shows senescence markers improving after curated plasmid